免疫治疗

参考文献

[1]. Louis, D.N., et al., The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol, 2021. 23(8): p. 1231-1251.

[2]. Ostrom, Q.T., et al., CBTRUS Statistical Report: Primary brain and other central nervous system tumors  diagnosed in the United States in 2010-2014. Neuro Oncol, 2017. 19(suppl_5): p. v1-v88.

[3]. Yuan, X.G., et al., Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases. Ann Hematol, 2020. 99(1): p. 93-104.

[4]. Langner-Lemercier, S., et al., Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol, 2016. 18(9): p. 1297-303.

[5]. Bataille, B., et al., Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg, 2000. 92(2): p. 261-6.

[6]. Weller, M., et al., Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol, 2012. 14(12): p. 1481-4.

[7]. Haque, S., et al., Imaging of lymphoma of the central nervous system, spine, and orbit. Radiol Clin North Am, 2008. 46(2): p. 339-61, ix.

[8]. Weller, M., et al., Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol, 2012. 14(12): p. 1481-4.

[9]. Labak, C.M., et al., Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review. World Neurosurg, 2019. 126: p. e1436-e1448.

[10]. Correa, D.D., et al., Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol, 2012. 14(1): p. 101-8.

[11]. Hottinger, A.F., et al., Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology, 2007. 69(11): p. 1178-82.

[12]. Rubenstein, J.L., et al., How I treat CNS lymphomas. Blood, 2013. 122(14): p. 2318-30.

[13]. Sun, A., et al., Phase III trial of prophylactic cranial irradiation compared with observation in  patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol, 2011. 29(3): p. 279-86.

[14]. Batchelor, T., et al., Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a  report of NABTT 96-07. J Clin Oncol, 2003. 21(6): p. 1044-9.

[15]. Gerstner, E.R., et al., Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology, 2008. 70(5): p. 401-2.

[16]. Herrlinger, U., et al., NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol, 2005. 57(6): p. 843-7.

[17]. Bokstein, F., et al., Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma, 2002. 43(3): p. 587-93.

[18]. Skarin, A.T., et al., High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood, 1977. 50(6): p. 1039-47.

[19]. Nabors, L.B., et al., Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2020. 18(11): p. 1537-1570.

[20]. Reni, M., et al., Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys, 2001. 51(2): p. 419-25.

[21]. Li, Q., et al., Improvement of outcomes of an escalated high-dose methotrexate-based regimen for  patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study. Cancer Manag Res, 2021. 13: p. 6115-6122.

[22]. Sieg, N., et al., Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine. Eur J Haematol, 2021. 107(2): p. 202-210.

[23]. Khan, R.B., et al., Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol, 2002. 58(2): p. 175-8.

[24]. Ferreri, A.J., et al., Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol, 2003. 21(12): p. 2407-14.

[25]. Ferreri, A.J., et al., High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, 2009. 374(9700): p. 1512-20.

[26]. Ferreri, A.J., et al., Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol, 2016. 3(5): p. e217-27.

[27]. Yu, J., et al., High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Sci Rep, 2021. 11(1): p. 2125.

[28]. Bergner, N., et al., Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database Syst Rev, 2012. 11: p. CD009355.

[29]. Soussain, C., et al., Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol, 2001. 19(3): p. 742-9.

[30]. Illerhaus, G., et al., High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol, 2006. 24(24): p. 3865-70.

[31]. Illerhaus, G., [Primary CNS lymphoma]. Dtsch Med Wochenschr, 2013. 138(49): p. 2515-8.

[32]. Soussain, C., et al., Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous  system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica, 2012. 97(11): p. 1751-6.

[33]. Schorb, E., et al., High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant, 2017. 52(8): p. 1113-1119.

[34]. Schorb, E., et al., Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica, 2013. 98(5): p. 765-70.

[35]. Pennese, E., et al., Complete response induced by fotemustine given as single agent in a patient with  primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support. Leuk Lymphoma, 2011. 52(11): p. 2188-9.

[36]. Gritsch, D., et al., Is Autologous Stem Cell Transplantation a Safe and Effective Alternative to Whole Brain Radiation as Consolidation Therapy in Patients With Primary Central Nervous System Lymphoma?: A Critically Appraised Topic. Neurologist, 2021. 26(4): p. 137-142.

[37]. Illerhaus, G., E. Schorb and B. Kasenda, Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood, 2018. 132(7): p. 681-688.

[38]. Pang, D.W., et al., [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2021. 29(4): p. 1175-1180.

[39]. Fu, J. and X. Ma, High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma. J BUON, 2021. 26(2): p. 366-372.

[40]. Miyakita, Y., et al., Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an  evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous  system lymphoma (PCNSL). Jpn J Clin Oncol, 2017. 47(10): p. 919-924.

[41]. Bromberg, J., et al., Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol, 2019. 20(2): p. 216-228.

[42]. Grommes, C., et al., Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol, 2019. 21(3): p. 306-313.

[43]. Grommes, C., et al., Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov, 2017. 7(9): p. 1018-1029.

[44]. Grommes, C., et al., Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory  CNS lymphoma. Blood, 2019. 133(5): p. 436-445.

[45]. Lv, L., et al., Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis. Front Oncol, 2021. 11: p. 707285.

[46]. Narita, Y., et al., Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol, 2021. 23(1): p. 122-133.

[47]. Fingar, D.C. and J. Blenis, Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 2004. 23(18): p. 3151-71.

[48]. Korfel, A., et al., Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. J Clin Oncol, 2016. 34(15): p. 1757-63.

[49]. Montesinos-Rongen, M., R. Siebert and M. Deckert, Primary lymphoma of the central nervous system: just DLBCL or not? Blood, 2009. 113(1): p. 7-10.

[50]. Chapuy, B., et al., Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood, 2016. 127(7): p. 869-81.

[51]. Courts, C., et al., Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol, 2007. 66(3): p. 230-7.

[52]. Braaten, K.M., et al., BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res, 2003. 9(3): p. 1063-9.

[53]. Makino, K., et al., BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma. J Neurooncol, 2018. 140(1): p. 115-121.

[54]. Ackler, S., et al., Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol Res Perspect, 2015. 3(5): p. e00178.

[55]. Gribben, J.G., N. Fowler and F. Morschhauser, Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol, 2015. 33(25): p. 2803-11.

[56]. Zhu, D., et al., Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother, 2008. 57(12): p. 1849-59.

[57]. Wu, L., et al., lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res, 2008. 14(14): p. 4650-7.

[58]. Tun, H.W., et al., Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood, 2018. 132(21): p. 2240-2248.

[59]. Chapuy, B., et al., Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood, 2016. 127(7): p. 869-81.

[60]. Roemer, M., et al., Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol, 2018. 36(10): p. 942-950.

[61]. Qiu, Y., et al., Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. Br J Haematol, 2018. 183(4): p. 674-678.

[62]. Nayak, L., et al., PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood, 2017. 129(23): p. 3071-3073.

[63]. Abramson, J.S., et al., Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. N Engl J Med, 2017. 377(8): p. 783-784.

[64]Grommes C, Pentsova E, Nolan C, et al. Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Ann. Oncol. 2016;27(suppl_6):103-113.

[65]Ghesquieres H, Houillier C, Chinot O, et al. Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a “proof of concept” phase II study of the French LOC Network [abstract]. Blood. 2016;128(22):785.